Dr Reddy’s Laboratories reported a business agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.

The acquired brands represent two types of products, (a) mometasone mono-product and (b) combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis.

MV Ramana, CEO, Branded Markets (India and Emerging Markets) of Dr Reddy’s said, “The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important core markets for us. Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients.

Recently, Dr Reddy’s Laboratories Ltd also announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL). Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin (Succinylcholine Chloride)Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA). The Quelicin brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health.